Northland Securities Reiterates “$20.00” Price Target for Flexion Therapeutics (NASDAQ:FLXN)

Share on StockTwits

Northland Securities set a $20.00 price objective on Flexion Therapeutics (NASDAQ:FLXN) in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued reports about the stock. ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Thursday, May 23rd. Zacks Investment Research raised shares of Flexion Therapeutics from a hold rating to a buy rating and set a $12.00 target price for the company in a research report on Saturday, August 10th. Finally, BidaskClub raised shares of Flexion Therapeutics from a hold rating to a buy rating in a research report on Wednesday, September 4th. Ten analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $23.57.

Shares of NASDAQ:FLXN traded down $0.21 on Tuesday, hitting $13.92. The company had a trading volume of 1,102 shares, compared to its average volume of 520,452. Flexion Therapeutics has a 1-year low of $8.76 and a 1-year high of $21.77. The stock has a market cap of $543.02 million, a price-to-earnings ratio of -3.11 and a beta of 1.23. The stock has a 50 day moving average price of $11.29 and a 200 day moving average price of $11.69. The company has a current ratio of 7.80, a quick ratio of 7.33 and a debt-to-equity ratio of 3.95.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.10. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%. The firm had revenue of $16.95 million for the quarter, compared to the consensus estimate of $14.03 million. Sell-side analysts anticipate that Flexion Therapeutics will post -4.02 earnings per share for the current fiscal year.

In other Flexion Therapeutics news, insider Michael D. Clayman bought 2,317 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 8th. The stock was bought at an average price of $10.85 per share, with a total value of $25,139.45. Following the completion of the transaction, the insider now owns 72,249 shares in the company, valued at approximately $783,901.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 16.01% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Quantamental Technologies LLC lifted its position in Flexion Therapeutics by 310.1% during the second quarter. Quantamental Technologies LLC now owns 3,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 2,608 shares during the period. Aperio Group LLC bought a new stake in Flexion Therapeutics during the second quarter worth about $46,000. Cutler Group LP lifted its position in Flexion Therapeutics by 2,650.0% during the second quarter. Cutler Group LP now owns 5,500 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 5,300 shares during the period. BNP Paribas Arbitrage SA lifted its position in Flexion Therapeutics by 53,692.3% during the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 6,980 shares during the period. Finally, Paradigm Capital Management Inc. NY bought a new stake in Flexion Therapeutics during the second quarter worth about $123,000. 84.87% of the stock is owned by institutional investors and hedge funds.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Recommended Story: Percentage Gainers

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cloverdale Capital Management LLC Buys 18,772 Shares of Mohawk Industries, Inc.
Cloverdale Capital Management LLC Buys 18,772 Shares of Mohawk Industries, Inc.
Perspecta Inc  Shares Sold by Cloverdale Capital Management LLC
Perspecta Inc Shares Sold by Cloverdale Capital Management LLC
Eminence Capital LP Invests $12.90 Million in Sothebys
Eminence Capital LP Invests $12.90 Million in Sothebys
Eminence Capital LP Has $26.53 Million Stake in Asbury Automotive Group, Inc.
Eminence Capital LP Has $26.53 Million Stake in Asbury Automotive Group, Inc.
Eminence Capital LP Cuts Holdings in TAKE-TWO INTERACTIVE SOFTWARE, INC
Eminence Capital LP Cuts Holdings in TAKE-TWO INTERACTIVE SOFTWARE, INC
Eminence Capital LP Sells 226,265 Shares of Thermo Fisher Scientific Inc.
Eminence Capital LP Sells 226,265 Shares of Thermo Fisher Scientific Inc.


© 2006-2019 Ticker Report